Beta Bionics Partners with Senseonics to Integrate Diabetes Management Systems
News related to:Beta Bionics · 1 min read
IRVINE, Calif., Sept. 22, 2026 /CourierPR/ -- Beta Bionics, a leader in diabetes management solutions, has announced a partnership with Senseonics to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system. This collaboration aims to provide people with diabetes with more choices in managing their condition.
According to Sean Saint, President and CEO of Beta Bionics, the integration of these systems will expand the reach of their advanced diabetes management solutions.
The commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026. At that time, Beta Bionics expects the iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users. The companies have also committed to the integration of mint and Eversense 365 in the future.
Beta Bionics, Inc. is a commercial-stage medical device company focused on the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes. The company's proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of people with diabetes.
In a forward-looking statement, the company noted that the integration of iLet and mint with Eversense 365 is expected to provide a compelling and differentiated choice for people with diabetes. The company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, provide additional details on the company's financial and operational outlook.
The partnership underscores Beta Bionics' and Senseonics' shared commitment to bringing cutting-edge diabetes solutions to the market, while maximizing choice for people living with diabetes.